FDA peptides restrictions could ease after panel recommendation
An FDA panel voted to ease limits on some peptides, NBC News reported, despite objections from agency scientists.
By Tom Brennan · Health & Medicine Correspondent
2 min read
An FDA panel recommendation on peptides could ease restrictions on some of the treatments, NBC News reported, a move that could affect how they are sold. The panel voted to loosen limits over objections from FDA scientists, according to NBC News.
The treatments are controversial because they are marketed for benefits that include muscle growth and weight loss, NBC News reported. The network’s Anne Thompson said the recommendation has drawn concern from people who do not think the products are a good idea.
What did the FDA panel recommend about peptides?
The FDA panel voted to ease restrictions on some peptides, according to NBC News. NBC News identified BPC-157 in its report on the panel’s action, while describing the broader category as popular treatments sold with claims tied to muscle growth, weight loss and other benefits.
NBC News described the action as a panel recommendation, not as a final agency rule. The report said the recommendation could affect the sale of peptides, signaling that the practical impact may depend on what federal regulators do next.
Why FDA scientists objected
NBC News reported that FDA scientists objected to the move, but the panel still voted in favor of easing restrictions on some peptides. The report did not detail each scientific objection in the excerpt available, but it framed the disagreement as a key reason the recommendation is contentious.
The split matters because FDA panels often bring outside review to questions involving safety, access and evidence. In this case, NBC News reported that the recommendation came despite concern from scientists inside the agency.
What are peptide treatments being marketed for?
NBC News described peptides as treatments that have become popular and are marketed for a range of claimed benefits. The examples cited by the network include muscle growth and weight loss.
The report did not say which products would be affected beyond its reference to some peptides and BPC-157. It also did not provide sales figures, patient data or a timeline for any broader FDA action.
The recommendation aired on NBC Nightly News on July 23, 2026. NBC News said Anne Thompson reported on why the treatments remain divisive and why the panel’s vote could change the market for some peptide products.
This story draws on original reporting from NBC News.